Brahmi vati in the treatment of psychological and behavioural symptoms of premenstrual women

EFFECT OF BRAHMI VATI IN THE MANAGEMENT OF PREMENSTURAL DYSPHORIC DISORDER Ã¢â?¬â??A RANDOMIZED DOUBLE BLIND CONTROLLED CLINICAL TRIALÃ¢â?¬?

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027855

Enrollment

Registered

2020-09-17

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F330- Major depressive disorder, recurrent, mild

Interventions

Intervention1: Group A -15 samples-Cap.Brahmi vati : Group A-Cap.Brahmi vati(500mg TID)for 60days Time of administration After food Anupana sukoshna jala Oral Route of administration Control Interven

Eligibility

Inclusion criteria

Inclusion criteria: 1.Irrespective of religion,occupation, economic status 2.Subjects fulfilling the diagnostic criteria of PSST(DSM V) 3.Symptoms occurring regularly for 5-7 days during luteal phase of last 3 menstural cycles 4.Symptom free during rest of the cycle

Exclusion criteria

Exclusion criteria: 1.Patient below 19yrs and above 30yrs 2.Patients with Major depressive disorder, Anxiety disorder,Psychosis etc., 3.Preganant woman,Lactating woman,any other organic lesions. 4.Hypothyroidism, Hyperthyroidism and PCOD cases

Design outcomes

Primary

Measure	Time frame
Ã¢â?¬Â¢Reduction in the score of Premenstural Dysphoric Disorder Questionnaire.Timepoint: 30days,60days,90days	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactDrKashavva V Hiremath

KAHERs Shri B M Kankanwadi Ayurveda Mahavidyalaya PG Studies and Medical Research Centre

kvhiremath.kaher@kleayurworld.edu.in9448945687

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026